We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma.
- Authors
Tomoyuki Satake; Taro Shibuki; Kazuo Watanabe; Mitsuhito Sasaki; Hiroshi Imaoka; Shuichi Mitsunaga; Motohiro Kojima; Masafumi Ikeda
- Abstract
Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver cancers. Therapeutic strategies for patients with cHCC-CCA are limited, and no standard systemic treatment has been established for unresectable cHCC-CCA. Here, we present six cases of cHCC-CCA treated with atezolizumab plus bevacizumab. We observed three partial responses and one stable disease as the best responses; two of these patients were still being treated with atezolizumab plus bevacizumab at the time of reporting (at least five months of treatment), whereas the remaining two patients were unable to continue treatment owing to adverse events. Atezolizumab plus bevacizumab may be an effective treatment for unresectable cHCC-CCA.
- Subjects
BEVACIZUMAB; ATEZOLIZUMAB; LIVER cancer; CHOLANGIOCARCINOMA
- Publication
Frontiers in Oncology, 2023, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2023.1234113